The 340B Drug Pricing Program is more than a pharmacy benefit; it is a lifeline for vulnerable communities and patients. However, as federal scrutiny and manufacturer challenges intensify, maintaining program integrity is no longer just about checking boxes; it is a strategic necessity. While internal self-auditing is essential, the independent 340B external audit serves as the definitive gold standard for ensuring long-term sustainability.
While the Health Resources and Services Administration (HRSA) recommends independent audits for covered entities with contract pharmacy arrangements, the value of these audits extends far beyond basic regulatory requirements.
- Objective Risk Mitigation: Internal teams, while diligent, often operate within the same operational silos they are auditing, which can lead to unconscious bias or overlooked system logic errors. External auditors bring a “neutral lens,” identifying blind spots in patient eligibility, diversion, and duplicate discount prevention before they escalate into federal findings.
- A Consultative Roadmap: Unlike HRSA audits, which are penal in nature, an independent external audit is a consultative experience. It provides a safe environment to test new practices, simulate HRSA timelines, and refine staff interviewing techniques through mock audit exercises.
- Operational Optimization: Independent auditors select data samples to identify trends and systemic gaps that internal reviews might miss. This comprehensive visibility doesn’t just catch errors but rather uncovers systemic inefficiencies that, when corrected, can actually expand program savings and patient reach.
- Stakeholder Confidence: For executive leadership and boards, an external audit report acts as an unbiased validation of the program’s health. In an era where 340B covered entities face scrutiny at significantly higher rates than manufacturers, having an “audit-ready” seal of approval is a vital reputational shield.
Relying solely on internal reviews can lead to a false sense of security. The most resilient 340B programs view external audits as a strategic investment in their mission. By proactively identifying and remediating gaps, organizations protect their right to participate in the program and ensure that every dollar saved continues to serve the patients who need it most.
For more information about the value of external audits or to inquire about scheduling an audit for your facility, please reach out to one of Blue & Co.’s 340B ACE-certified experts.
Kyle Smith, CPA, 340B ACE, Director
Jason Prokopik, PharmD, 340B ACE, Senior Manager
